Expand all sections

Belzutifan

Extended indication The treatment of adult patients with von Hippel-Lindau disease who require therapy for associated re
Therapeutic value No estimate possible yet
Total cost 4,312,500.00
Registration phase Registration application pending

Product

Active substance Belzutifan
Domain Oncology
Reason of inclusion New medicine (specialité)
Extended indication The treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and for whom localized procedures are unsuitable or undesirable.
Manufacturer MSD
Portfolio holder MSD
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)
Additional remarks Mode of action: HIF-2α inhibitor

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date December 2023
Expected Registration January 2025
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
Substantiation De behandeling van deze kleine groep patiënten lijkt op de behandeling van andere patiënten met een gemetastaseerd niercarcinoom. Verdere resultaten worden nog afgewacht.

Expected patient volume per year

Patient volume

10 - 15

Market share is generally not included unless otherwise stated.
Additional remarks based on clinical VHL experts input

Expected cost per patient per year

Cost < 345,000.00
References Drugs.com
Additional remarks In de VS kost belzutifan $31,243voor 90 tableten, wat neerkomt op een maand verbruik. Per jaar zou dat omgerekend ongeveer €345.000 kosten. De kosten in de EU zullen waarschijnlijk lager uitvallen.

Potential total cost per year

Total cost

4,312,500.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.